The Medicines Co. Newsletter
-
CIRM awards US$ 4 mn grant to Entos Pharma to advance development of ENTLEP001, a durable and redosable genetic medicine to treat CGL
07 Feb 2025 09:31 GMT
… (Entos), a clinical-stage genetic medicines company committed to using its Fusogenix …
-
Raplixa Global Market Report 2025: In-Depth Analysis of Trends, Forecasts & Market Dynamics
06 Feb 2025 17:55 GMT
… industry players such as The Medicines Company. It's beneficial to …
-
Biotechs Chroma, Nvelop merge to form genetic medicines company
11 Dec 2024 12:29 GMT
-
Entos Pharmaceuticals Awarded $4 Million USD in Funding from the California Institute for Regenerative Medicine (CIRM) for its Congenital Generalized Lipodystrophy Program
05 Feb 2025 16:17 GMT
… (Entos), a clinical-stage genetic medicines company committed to using its Fusogenix …
-
Novo Partner Omega Waves Bankruptcy Flag from Sinking Ship
04 Feb 2025 23:09 GMT
… cash runway fizzles, the epigenomic medicines company has entered into a restructuring …
-
Omega Therapeutics nears bankruptcy filing, lays off workers
04 Feb 2025 23:09 GMT
… the next week, the epigenomic medicines company said in a filing, a …
-
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
04 Feb 2025 16:30 GMT
… : ARCT), a commercial messenger RNA medicines company focused on the development of …
-
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04 Feb 2025 16:29 GMT
… “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational …
-
From Underperformance to Opportunity Biotechs Case for 2025
01 Feb 2025 16:16 GMT
… -strategic-transformation-leading-focused-innovative-medicines-company
¹⁰Source: https://investors …
-
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
31 Jan 2025 21:15 GMT
… “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational …